Please login to the form below

Not currently logged in
Email:
Password:

Liponova signs MOU for renal cancer vaccine

LipoNova signs a Memorandum of Understanding for the development and marketing of its non-metastatic renal cell carcinoma candidate vaccine Reniale with an unnamed non-European partner

German biopharmaceutical and vaccines company LipoNova has signed a Memorandum of Understanding (MoU) for the development and marketing of its non-metastatic renal cell carcinoma (RCC) candidate vaccine Reniale with an as yet unnamed non-European pharmaceutical company.

The MoU provides for milestone payments and ongoing royalties on sales of Reniale. LipoNova's partner will win an exclusive licence for marketing the product to a non-European country. The partner will, on conclusion of the agreement, support an international phase III study and be involved in possible 'named patients' programmes.

Liponova's executive board says the MoU is an important step in the development and marketing of Reniale outside Europe. The deal shows that foreign companies are very interested in marketing Reniale and therefore provides further evidence or Reniale's market potential. The company added that it aimed to launch Reniale on other non-European markets.

For H1 2007, Liponova made a loss of EUR 2.3m, compared with a loss of just under EUR 1m in H1 FY06. The increased loss was due to extra consultancy costs incurred in 2007 over preparations for the Reniale phase III study, while the company is still not making any significant sales.

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics